IMPROVE-IT : Are we back to the lower the better? Further LDL-Cholesterol lowering on top of statins: backgrounds and the results of the study
|
|
- Arthur Howard
- 5 years ago
- Views:
Transcription
1 IMPROVE-IT : Are we back to the lower the better? Further LDL-Cholesterol lowering on top of statins: backgrounds and the results of the study Fundación Fernández-Cruz Clinico San Carlos, Madrid Spain, 26 oct 2015 Prof. Dr. J.W. Jukema Dept Cardiology, Leiden University Medical Center The Netherlands
2 DISCLOSURE: JW Jukema has received research grants from and/or was speaker (with or without lecture fees) on (CME accredited) meetings sponsored by Amgen, Astellas, Anthera, Astra-Zeneca, Bayer, Biotronik, Boston Scientific,Correvio, Daiichi Sankyo, Lilly, Genzyme, Medtronic, Merck-Schering-Plough, Pfizer, Orbus Neich, Novartis, Roche, Servier, Sanofi Aventis, The Medicine Company, the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands and the European Community Framework KP7 Programme
3 Old
4 New
5 Further LDL-C lowering: Go / Hold/ Stop?
6 Nicolai Anitschkow ( ) Identified cell types involved in atherosclerosis Smooth muscle cells Macrophages Lymphocytes There is no atherosclerosis without cholesterol Anitschkow NN, Chatalov S (1913). "Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse". Zentralbl Allg Pathol 24: 1-9. Anitschkow NN (1913). "Über die Veränderungen der Kaninchenaorta bei experimenteller Cholesterinsteatose". Beitr Pathol Anat 56:
7 CTT: more intensive LDL lowering can decrease CV events by 40-50% Event (% per annum) Statin/more Control/less RR (CI) per 1 mmol/l reduction in LDL-C Trend test More vs less statin <2 mmol/l 2 to <2.5 mmol/l 2.5 to <3.0 mmol/l 3 to <3.5 mmol/l 3.5 mmol/l Total 704 (4.6%) 1189 (4.2%) 1065 (4.5%) 517 (4.5%) 303 (5.7%) 3837 (4.5%) 795 (5.2%) 1317 (4.8%) 1203 (5.0%) 633 (5.8%) 398 (7.8%) 4416 (5.3%) 0.71 ( ) 0.77 ( ) 0.81 ( ) 0.61 ( ) 0.64 ( ) 0.72 ( ) 1 X2 =2.04 (p=0.2) Statin vs contol <2 mmol/l 2 to <2.5 mmol/l 2.5 to <3.0 mmol/l 3 to <3.5 mmol/l 3.5 mmol/l Total All trials combined 206 (2.9%) 339 (2.4%) 801 (2.5%) 1490 (2.9%) 4205 (2.9%) 7136 (2.8%) 217 (3.2%) 412 (2.9%) 1022 (3.2%) 1821 (3.6%) 5338 (3.7%) 8934 (3.6%) 0.87 ( ) 0.77 ( ) 0.76 ( ) 0.77 ( ) 0.80 ( ) 0.79 ( ) 1 X2 =0.80 (p=0.4) <2 mmol/l 2 to <2.5 mmol/l 2.5 to <3.0 mmol/l 3 to <3.5 mmol/l 3.5 mmol/l Total 910 (4.1%) 1528 (3.6%) 1866 (3.3%) 2007 (3.2%) 4508 (3.0%) (3.2%) 1012 (4.6%) 1729 (4.2%) 2225 (4.0%) 2454 (4.0%) 5736 (3.9%) (4.0%) 0.78 ( ) 0.77 ( ) 0.77 ( ) 0.76 ( ) 0.80 ( ) 0.78 ( ) 1 X2 =1.08 (p=0.3) 99% or 95% CI Statin/more better Control/less better Cholesterol Treatment Trialists (CTT) Collaboration. Lancet. 2010;376:
8 Propotional reduction of coronary events Effect of LDL-C Lowering with Statins CTT prospective meta-analysis, 14 randomised studies, n = % relative risk reduction per 1 mm/l (38.7mg/dl) LDL- C lowering LDL-C lowering [mmol/l] Cholesterol Treatment Trialists (CTT), Lancet 2005; 366:
9 Statin landmark trials
10 STATINS Safety: In general good safety profile!
11 How (Low) Should We Go? How low is normal? Where does less progression change into induced regression? How can we go that low?
12 IVUS Allows for Determination of Atherosclerosis Burden by Total Plaque Volume 3.1 mm 3.1 mm
13 Change in TAV (%) Reversal Primary end point: Percent change in total atheroma volume P= * Pravastatin -0.4 Atorvastatin Significant atherosclerotic progression from baseline *Progression vs baseline (P=0.001); No change vs baseline (P=0.98) No significant change from baseline; atherosclerotic progression was stopped Nissen SE et al. JAMA Mar 3;291(9):
14 Comparison of LDL-C reduction and change in atheroma volume Change in Atheroma Volume, mm Both Treatment Groups (n=502) % Change in Low-Density Lipoprotein Cholesterol Regardless of the agent used, an LDL-C reduction of at least 50% was required to halt progression. The dashed lines indicate upper and lower 95% CIs for the mean values
15 How (Low) Should We Go? How low is normal? Where does less progression change into induced regression? How can we go that low?
16 reduction of LDL (%) Statins: Rule of six mg +20 mg +40 mg % - 6% -50-6% mg Statin
17 LDL-C Reduction across separate studies (no direct comparisons) Rosuvastatin 10 mg (-46%) mg 20 mg 40 mg 10 mg 20 mg 40 mg 80 mg rosuvastatin atorvastatin simvastatin 10 mg 20 mg 40 mg 80 mg pravastatin Ezetimibe /simvastatin 10 mg 20 mg 40 mg 10/20 10/40 10/80 Ezetimibe/simvastatin 10/20mg (-51%) Adapted from Goldberg AC et al Mayo Clin Proc 2004;79: ; Jones PH et al Am J Cardiol 2003;92:
18 Therapy for atherosclerosis Do we need a new drug to expand our therapeutic alternatives? Many statin patients are treated unsatisfactorily and do not reach their therapeutic goals, even with higher doses Doubling the dose of statin decreases LDL cholesterol by only another 6 % Increasing doses of statins are connected with higher risk of adverse events Non-statin additives/alternatives?
19 Non-fatal myocardial infarction or CHD death Relative Risk reduction (%) Estimated change in the five-year relative risk. LDL-C reduction (%) Robinson, J Am Coll Cardiol 2005;46: )
20 Dual Inhibition: Ezetimibe and Statin Statin Synthesis of Cholesterol Bile Cholesterol absorption Intestine DAR Ezetimibe Dietary cholesterol Excretion
21 LDL-C Reduction 3 steps of titration with statins or 1 step with Ezetimibe co-administration? Statin 10 mg 20 mg 40 mg 80 mg 3-fold TITRATION Statin10 mg +Ezetimibe 10 mg SIMPLE CO- ADMINISTRATION % reduction of LDL-cholesterol
22 Ezetimibe: Background Ezetimibe inhibits Niemann-Pick C1-like 1 (NPC1L1) protein located primarily on the epithelial brush border of the GI tract resulting in reduced cholesterol absorption When added to statin, produces ~20% further reduction in LDL-C Two recent human genetic analyses have correlated polymorphisms in NPC1L1 with lower levels of LDL-C and lower risk of CV events* *MI Genetics Consortium Investigators NEJM 2014; online Nov 12; Ference BA et al
23 The proof of the pudding is the long term eating Evidence from Trials!
24 Theory, Hypothesis, Test! Wrong Conclusion! You Need Clinical Trials to Adequately Test Your Hypothesis!!
25 Ezetimibe Reduces Carotid Artery Atherosclerosis in apoe Knockout Mice* Control Ezetimibe 5 mg/kg/d * Mice fed 0.15% cholesterol diet for 6 months Davis et al. Atherosclerosis. 2000; 151:133 (Abs).
26 IMProved Reduction of Outcomes: Vytorin Efficacy International Trial A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome
27 Goals IMPROVE-IT: First large trial evaluating clinical efficacy of combination EZ/Simva vs. simvastatin (i.e., the addition of ezetimibe to statin therapy): Does lowering LDL-C with the non-statin agent ezetimibe reduce cardiac events? Is (Even) Lower (Even) Better? (estimated mean LDL-C ~50 vs. 65mg/dL) Safety of ezetimibe Cannon CP AHJ 2008;156:826-32; Califf RM NEJM 2009;361:712-7; Blazing MA AHJ 2014;168:205-12
28
29 Major worries regarding the design of the IMPROVE-IT trial 1) Low absolute event rates 2) High drop-out/loss to follow-up 3) Very low baseline LDL-c levels law of diminishing returns
30 Absolute CV Risk [%] Diminishing absolute risk reduction for lower absolute LDL-C reduction with lower baseline LDL-C Relative Risk reduction -20% -15% -11% -4% mmol mmol mmol - 1 mmol 4 LDL-C [mg/dl] % -25% -25% -25%
31 Are you still there?
32
33 Inclusion Criteria: Patient Population Hospitalization for STEMI, NSTEMI/UA < 10 days Age 50 years, and 1 high-risk feature: New ST chg, + troponin, DM, prior MI, PAD, cerebrovasc, prior CABG > 3 years, multivessel CAD LDL-C mg/dl ( mg/dl if prior lipid-lowering Rx) Major Exclusion Criteria: CABG for treatment of qualifying ACS Current statin Rx more potent than simva 40mg Creat Cl < 30mL/min, active liver disease
34 Patients stabilized post ACS 10 days: LDL-C *mg/dL (or **mg/dL if prior lipid-lowering Rx) N=18,144 Standard Medical & Interventional Therapy Simvastatin 40 mg Study Design Uptitrated to Simva 80 mg if LDL-C > 79 (adapted per FDA label 2011) *3.2m M **2.6m M Ezetimibe / Simvastatin 10 / 40 mg Follow-up Visit Day 30, every 4 months 90% power to detect ~9% difference Duration: Minimum 2 ½-year follow-up (at least 5250 events) Primary Endpoint: CV death, MI, hospital admission for UA, coronary revascularization ( 30 days after randomization), or stroke Cannon CP AHJ 2008;156:826-32; Califf RM NEJM 2009;361:712-7; Blazing MA AHJ 2014;168:205-12
35 Baseline Characteristics Simvastatin (N=9077) % EZ/Simva (N=9067) % Age (years) Female Diabetes MI prior to index ACS STEMI / NSTEMI / UA 29 / 47 / / 47 / 24 Days post ACS to rand (IQR) 5 (3, 8) 5 (3, 8) Cath / PCI for ACS event 88 / / 70 Prior lipid Rx LDL-C (mg/dl) (IQR) 95 (79, 110) 95 (79,110)
36 Study Metrics Simva (N=9077) EZ/Simva (N=9067) Uptitration to Simva 80mg, % 27 6 Premature study drug D/C, % Median follow-up, yrs WDC without vital status, %/yr Lost to follow-up, %/yr Follow up for primary endpoint, % Follow up for survival, % Total primary endpoint events = 5314 Total patient-years clinical follow-up = 97,822 Total patient-years follow-up for survival = 104,135
37 LDL-C and Lipid Changes 1 Yr Mean LDL-C TC TG HDL hscrp Simva EZ/Simva Δ in mg/dl Median Time avg 69.5 vs mg/dl
38 Primary and 3 Prespecified Secondary Endpoints ITT Simva* EZ/Simva*p-value Primary CVD/MI/UA/Cor Revasc/CVA Secondary # All D/MI/UA/Cor Revasc/CVA Secondary # CHD/MI/Urgent Cor Revasc Secondary # CVD/MI/UA/All Revasc/CVA Ezetimibe/Simva Better Simva Better *7-year event rates (%) UA, documented unstable angina requiring rehospitalization; Cor Revasc, coronary revascularization ( 30 days after randomization); All D, all-cause death; CHD, coronary heart disease death; All Revasc, coronary and non-coronary revascularization ( 30 days)
39 Individual Cardiovascular Endpoints and CVD/MI/Stroke HR Simva* EZ/Simva* p-value All-cause death CVD CHD MI Stroke Ischemic stroke Cor revasc 30d UA CVD/MI/stroke Ezetimibe/Simva Better Simva Better *7-year event rates (%)
40 CV Death, Non-fatal MI, or Non-fatal Stroke HR 0.90 CI (0.84, 0.97) p=0.003 NNT= 56 Simva 22.2% 1704 events EZ/Simva 20.4% 1544 events 7-year event rates
41 For which situation the parachute will protect best?
42 Major Pre-specified Subgroups Simva EZ/Simva Male Female Age < 65 years Age 65 years No diabetes Diabetes * Prior LLT No prior LLT LDL-C > LDL-C Ezetimibe/Simva Better Simva Better 7-year event rates *p-interaction = 0.023, otherwise > 0.05
43 IMPROVE-IT vs. CTT: Ezetimibe vs. Statin Benefit CTT Collaboration. Lancet 2005; 366: ; Lancet 2010;376: NEJM 2015;372:
44 Safety: Again no problem!
45 Safety ITT No statistically significant differences in cancer or muscle- or gallbladder-related events Simva n=9077 % EZ/Simva n=9067 % p ALT and/or AST 3x ULN Cholecystectomy Gallbladder-related AEs Rhabdomyolysis* Myopathy* Rhabdo, myopathy, myalgia with CK elevation* Cancer* (7-yr KM %) * Adjudicated by Clinical Events Committee % = n/n for the trial duration
46 Primary outcome - NODM HR 1.04 (95% CI ) p = , Decreased risk with Ez/Simva Increased risk with Ez/Simva NODM = antihypergycemic med and/or 2 fasting glucoses > 7 mmol/l
47 Conclusions IMPROVE-IT: First trial demonstrating incremental clinical benefit when adding a non-statin agent (ezetimibe) to statin therapy: YES: Non-statin lowering LDL-C with ezetimibe reduces cardiovascular events YES: Even Lower is Even Better (achieved mean LDL-C 53 vs. 70 mg/dl at 1 year) YES: Confirms ezetimibe safety profile Reaffirms the LDL hypothesis, that reducing LDL-C prevents cardiovascular events Results could be considered for future guidelines
48
49 Statin Therapy and Incident Diabetes Statin Placebo or Control n Events Rate Events Rate OR (95% CI) Weight (%) ASCOT-LLA ( ) 7.07% HPS 14, ( ) 13.91% JUPITER 17, ( ) 11.32% WOSCOPS ( ) 4.24% LIPID ( ) 6.53% CORONA ( ) 4.65% PROSPER ( ) 6.94% MEGA ( ) 8.03% AFCAPS/TEXCAPS ( ) 3.76% 4S ( ) 8.88% ALLHAT ( ) 10.23% GISSI HF ( ) 9.50% GISSI PREV ( ) 4.94% Overall (I 2 = 11.2% [95% CI %] 1.09 ( ) 100% Sattar N et al. Lancet 2010;375:735-42
50 Meta-Analysis of New-Onset Diabetes and First Major Cardiovascular Events in Trials Comparing Intensive- to Moderate-Dose Statin Therapy Preiss D et al. JAMA 2011;305:
51 Achievement of Dual LDL-C (<70 mg/dl) and hs- CRP (<2 mg/l) Targets More Frequent with Addition of Ezetimibe to Simvastatin and Associated with Better Outcomes in IMPROVE IT From the data presentation at ESC 2015 (London, UK) by Erin A. Bohula May, Robert P. Giugliano, Christopher P. Cannon, Jing Zhou, Amy McCagg, Michael A. Blazing, Jennifer A. White, Andrew M. Tershakovec, & Eugene Braunwald Published in Circulation Aug : Circulation. 2015;132: DOI: /CIRCULATIONAHA Circulation. 2015;132: DOI: /CIRCULATIONAHA
52 Pre-specified LDL-C and hs-crp Target Achievement at 1 month by randomized Treatment The addition of ezetimibe to simvastatin resulted in significant reductions in LDL-C and hs-crp compared to simva monotherapy (p<0.001), translating to significantly more patients meeting both of the targets: 50% versus 29%, p<0.001 Circulation. 2015;132: DOI: /CIRCULATIONAHA
53 Primary Endpoint by 1 month Pre-specified LDL- C and/or hs-crp Target Achievement After adjustment, achieving both targets at 1 month was associated with a 27% lower relative risk in the primary composite endpoint compared to meeting neither LDL-C nor hs-crp target at 1 month. An analysis of the secondary and individual endpoints suggested that relative to achieving neither target, meeting both targets was associated with a significant improvement in outcomes, with the exceptionof stroke. Circulation. 2015;132: DOI: /CIRCULATIONAHA
54 Conclusion In this pre-specified analysis of the IMPROVE-IT trial, patients were significantly more likely to achieve LDL-C and hs-crp targets with EZ/simva vs simva monotherapy. There was a graded association of improved outcomes with target achievement for the primary endpoint. The specific therapy used to attain target levels did not differentially impact outcomes, suggesting that in this analysis target achievement is more important than the specific choice of agent used to achieve the target Circulation. 2015;132: DOI: /CIRCULATIONAHA
55 Questions? 1. One of the excl. criteria was use of statin therapy that had LDL cholesterol lowering potency greater than 40 mg of simvastatin. Based on the IMPROVE-IT results which secondary prevention therapy, if needed, would you recommend when patients are already on simvastatin 40 mg and well tolerated? 2. Knowing that for a period (till June 2011) 80 mg simvastatin was allowed in a blinded manner. Between October 26, 2005, and July 8, 2010, a total of 18,144 patients underwent randomization at 1147 sites in 39 countries, therefore all patients could receive 80 mg? The simvastatin dose was increased to 80 mg for elevated LDL cholesterol levels in 27% of the patients in the simvastatin-monotherapy group and in 6% of the patients in the simvastatin ezetimibe group. What is your opinion on the allowance of 80 mg simvastatin in both groups on the prim. Endpoint? 3. What is your opinion on the fact that the benefit appeared to be particularly pronounced in patients with diabetes mellitus and in patients 75 years of age or older. Moreover we see in other ACS studies a particularly pronounced effect within the diabetes population? 4. Could you explain the significant differences in Urgent coronary revascularization 30 days after randomization? 5. Is the Improve-IT trial a secondary prevention trial or a chronic phase trial if we take into account the benefit only after one year?
IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
IMProved Reduction of Outcomes: Vytorin Efficacy International Trial A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet)
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationIMProved Reduction of Outcomes: Vytorin Efficacy International Trial
Trial Leadership IMProved Reduction of Outcomes: Vytorin Efficacy International Trial A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/statin
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationThe Resurrection of Ezetimibe: A Story of Perseverance
The Resurrection of Ezetimibe: A Story of Perseverance Harry Chip Davis CVPath Institute Gaithersburg, MD (Schering-Plough / Merck) 1 Ezetimibe Inhibits Intestinal Cholesterol Uptake and Absorption (Discovered
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationHyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine
Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine The new england journal of medicine Original Article Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationAIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)
AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) Jacques Genest MD Cardiovascular Research Laboratory McGill University Health Center Disclosure J. Genest MD 2012 Advisory Board, Speaker s Bureau, Consultant,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationLipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011
Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011 Disclosure of Conflicts of Interest I have received travel grants and honoraria from sanofi-aventis, Pfizer, Servier,
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationZEUS Trial ezetimibe Ultrasound Study
Trial The lower, The better Is it True for Plaque Regression? Statin alone versus Combination of Ezetimibe and Statin Juntendo University, Department of Cardiology, Tokyo, Japan Katsumi Miyauchi, Naohisa
More informationREAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease
REAL-CAD : Cardiovascular benefit of pitavastatin in stable coronary artery disease Soo-Joong Kim M.D., PhD. Department of Cardiology, Internal Medicine, Kyung Hee University Hospital I have nothing to
More informationTHE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationStatins ARE Enough For The Prevention of CVD! Professor Kausik Ray Imperial College London, UK
1 Disclosures Advisory boards PCSK9- Sanofi/ Regeneron, Amgen, Pfizer, Roche, MSD NLI/ SC member for Odyssey- (Sanofi/ Regeneron), Roche Investigator initiated research grant support (Sanofi/Regeneron/
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationFarmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia. Prof. Alberto Corsini University of Milan, Italy
Farmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia Prof. Alberto Corsini University of Milan, Italy Outline of the presentation State of the art on statin therapy Explore unmet
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationSTATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP
STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC Director of Preventative Cardiology CGH Medical Center, Sterling, Illinois
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationIl rischio residuo nella persona con diabete: come individuarlo e come trattarlo?
Il rischio residuo nella persona con diabete: come individuarlo e come trattarlo? Alberto Zambon University of Padova - Italy DISCLOSURE - CONFLICT OF INTEREST Prof. A. Zambon reports having received grants,
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More information2/10/2016. Is it Time to Return to Cholesterol Goals for Optimal Patient Management? CON. Disclosures. Stipulations
Is it Time to Return to Cholesterol Goals for Optimal Patient Management? CON Donald M. Lloyd-Jones MD ScMFACC FAHA Eileen M. FoellProfessor Chair, Dept. of Preventive Medicine Senior Associate Dean Director,
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationGuidelines for the Management of Dyslipidaemias
Guidelines for the Management of Dyslipidaemias Etienne PUYMIRAT Département de Cardiologie Hôpital Européen Georges Pompidou Université Paris Descartes, Paris, France Fees for lectures and/or consulting:
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists Collaboration.
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationCurriculum Vitae Name : Prof. DR. Dr. Idrus Alwi SpPD, K-KV, FACC, FESC, FAPSIC, FINASIM, FACP. Current Position : Professor of Internal Medicine,
Curriculum Vitae Name : Prof. DR. Dr. Idrus Alwi SpPD, K-KV, FACC, FESC, FAPSIC, FINASIM, FACP. Current Position : Professor of Internal Medicine, Faculty of Medicine, UI Medical Student : Faculty of Medicine
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More information